MONTREAL, Nov. 15, 2024 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is extremely disappointed that negotiations for PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection), a treatment for patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), with the pan-Canadian Pharmaceutical Alliance (pCPA) have closed without an agreement.
Read more at newswire.cahello world
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
